Nathan Clumeck

20.8k total citations · 4 hit papers
238 papers, 12.7k citations indexed

About

Nathan Clumeck is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Nathan Clumeck has authored 238 papers receiving a total of 12.7k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Infectious Diseases, 99 papers in Epidemiology and 84 papers in Virology. Recurrent topics in Nathan Clumeck's work include HIV/AIDS drug development and treatment (92 papers), HIV Research and Treatment (83 papers) and HIV/AIDS Research and Interventions (63 papers). Nathan Clumeck is often cited by papers focused on HIV/AIDS drug development and treatment (92 papers), HIV Research and Treatment (83 papers) and HIV/AIDS Research and Interventions (63 papers). Nathan Clumeck collaborates with scholars based in Belgium, United Kingdom and France. Nathan Clumeck's co-authors include Mark Nelson, Eduardo Lissen, Francesca J. Torriani, Ricard Solà, Mark Sulkowski, Diethelm Messinger, Doug Dieterich, Julio Montaner, David L. Thomas and Richard K. Sterling and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Nathan Clumeck

229 papers receiving 12.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡

2006 3.5k citations Nathan Clumeck, Francesca J. Torriani et al. profile →
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

2013 593 citations Nathan Clumeck et al. New England Journal of Medicine profile →
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

2008 570 citations Roy M. Gulick, Jacob Lalezari et al. New England Journal of Medicine profile →
ACQUIRED IMMUNODEFICIENCY SYNDROME IN RWANDA

1984 436 citations Nathan Clumeck et al. profile →

Peers

Countries citing papers authored by Nathan Clumeck

Since Specialization

Citations

This map shows the geographic impact of Nathan Clumeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Clumeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Clumeck more than expected).

Fields of papers citing papers by Nathan Clumeck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Clumeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Clumeck. The network helps show where Nathan Clumeck may publish in the future.

Co-authorship network of co-authors of Nathan Clumeck

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Clumeck. A scholar is included among the top collaborators of Nathan Clumeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Clumeck. Nathan Clumeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial 2016 ·The Lancet HIV ·Joel E. Gallant, Eric S. Daar, François Raffi, Cynthia Brinson, Peter Ruane, Edwin DeJesus, Margaret Johnson, Nathan Clumeck, Olayemi Osiyemi, (unknown), Javier O Morales-Ramirez, Mingjin Yan, Michael E. Abram, Andrew Plummer, Andrew Cheng, Martin S. Rhee	127
2	Sustained Viral Suppression and Higher CD4+ T-Cell Count Reduces the Risk of Persistent Cervical High-Risk Human Papillomavirus Infection in HIV-Positive Women 2013 ·The Journal of Infectious Diseases ·Déborah Konopnicki, Yannick Manigart, Christine Gilles, Patricia Barlow, (unknown), Francesco Feoli, Denis Larsimont, Marc Delforge, Stéphane De Wit, Nathan Clumeck	61
3	A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1 2009 ·The Journal of Infectious Diseases ·Michael S. Saag, James Goodrich, Gerd Fätkenheuer, Bonaventura Clotet, Nathan Clumeck, John F. Sullivan, Mike Westby, Elna van der Ryst, Howard Mayer, (unknown)	108
4	Indicator disease‐guided testing for HIV – the next step for Europe? 2008 ·HIV Medicine ·B Gazzard, Nathan Clumeck, A. D’Arminio Monforte, Jens Lundgren	37
5	Maraviroc for Previously Treated Patients with R5 HIV-1 Infection breakdown → 2008 ·New England Journal of Medicine ·Roy M. Gulick, Jacob Lalezari, James Goodrich, Nathan Clumeck, Edwin DeJesus, Andrzej Horban, Jeffrey P. Nadler, Bonaventura Clotet, Anders Karlsson, Michael Wohlfeiler, (unknown), (unknown), John F. Sullivan, Caroline E. Ridgway, Steve Felstead, Michael W. Dunne, Elna van der Ryst, Howard Mayer	570
6	Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection 2008 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Milos Opravil, Joe Sasadeusz, David A. Cooper, Jürgen K. Rockstroh, Nathan Clumeck, Bonaventura Clotet, Joan Montaner, Francesca J. Torriani, Jean DePamphilis, Douglas T. Dieterich	46
7	The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003 2004 ·Cancer ·Amanda Mocroft, Ole Kirk, Nathan Clumeck, (unknown), H Trocha, Nelly Chentsova, Francisco Antunes, Hans‐Jürgen Stellbrink, Andrew Phillips, Jens Lundgren	102
8	European guidelines for the clinical management and treatment of HIV-infected adults in Europe 2003 ·AIDS ·Nathan Clumeck, Stéphane De Wit, Philippe Hermans, Robert Colebunders, Peter Reiss, Anders Sönnerborg, Vincent Soriano, Anne–Mieke Vandamme, M Youle	43
9	Recently diagnosed sexually HIV-infected patients: seroconversion interval, partner notification period and a high yield of HIV diagnoses among partners 2001 ·QJM ·A M Worm, Sheila M. Bird, (unknown), (unknown), (unknown), Hilde Colpin, Nathan Clumeck, Kevin Fenton, Robert M. French, O Haikala, (unknown), G. Papaevangelou, Harald Moi, (unknown), (unknown), A Scoular, Kristina Ramstedt, (unknown)	13
10	Acute pulmonary hypertension following paclitaxel in a patient with AIDS-related primary effusion lymphoma 2001 ·Clinical Microbiology and Infection ·Soraya Cherifi, P. Hermans, (unknown), Brigitte Cantinieaux, Nathan Clumeck	3
11	Update on highly active antiretroviral therapy: progress and strategies 2000 ·Biomedicine & Pharmacotherapy ·Nathan Clumeck, S. De Wit	16
12	Neutropenia in Patients with HIV Infection: A Case Control Study in a Cohort of 1403 Patients Between 1982 and 1993 1999 ·Journal of Hematotherapy & Stem Cell Research ·P. Hermans, (unknown), (unknown), Nathan Clumeck	11
13	Single Cell Analysis of Antigen-Specific T Cell Responses in HIV-Infected Individuals 1999 ·Cellular Immunology ·B. Byl, Michèle Gérard, Myriam Libin, Nathan Clumeck, Michel Goldman, Françoise Mascart	7
14	Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients 1996 ·Antiviral Therapy ·Schlomo Staszewski, Veronica Miller, (unknown), Robert Colebunders, Bernard Vandercam, J Delescluse, Nathan Clumeck, Filip Van Wanzeele, Marc De Brabander, J. De Crée, Marc Moeremans, Koen Andries, Charles A. Boucher, Paul Stoffels, Paul A. J. Janssen	5
15	Treatment of progressive multifocal leukoencephalopathy (PLM) with Cidofovir in an AIDS patient 1996 ·Antiviral Research ·Robert Snoeck, Stéphane De Wit, Camélia Rossi, (unknown), (unknown), (unknown), Jan Balzarini, (unknown), Serge Goldman, Nathan Clumeck	5
16	Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter 1993 ·New England Journal of Medicine ·David A. Cooper, José M. Gatell, Susanne Kroon, Nathan Clumeck, Judith Millard, Frank-D. Goebel, Johan N. Bruun, Georg Stingl, (unknown), Juan González‐Lahoz, John Stevens, A. P. Fiddian	161
17	Treatment of acute toxoplasmosis with intravenous clindamycin 1991 ·European Journal of Clinical Microbiology & Infectious Diseases ·Brian Dannemann, J. A. McCutchan, Dennis Israelski, Diana Antoniskis, C. Leport, Benjamin J. Luft, (unknown), J. L. Vildé, (unknown), Manuel Orellana, (unknown), John M. Leedom, Nathan Clumeck, P. Morlat, Jack S. Remington, (unknown)	10
18	SEPTICEMIE ET PERITONITE 'SPONTANEE' CHEZ LE CIRRHOTIQUE 1979 ·Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) ·Nathan Clumeck, Marc Estenne, R. Vanhoof	3
19	Is nasogastric suction necessary in acute pancreatitis? 1978 ·BMJ ·Robert Naeije, (unknown), Nathan Clumeck, André De Troyer, Ghislain Devis	46
20	Treatment of diabetic coma with small intravenous insulin boluses. 1976 ·BMJ ·Nathan Clumeck, André De Troyer, Robert Naeije, G. Somers, (unknown), Edmond Balasse	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact